Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-10-24
2009-12-22
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07635714
ABSTRACT:
A compound of Formula (1) or a pharmaceutically acceptable salt thereof:wherein R1represents a C1-C6alkyl group and R2represents a C1-C6alkyl group, while unlike a laxative, is effective in the treatment of constipation.
REFERENCES:
patent: 6562795 (2003-05-01), Ashley et al.
patent: 1314737 (2003-05-01), None
patent: 2001-119295 (2000-04-01), None
patent: WO 93/13780 (1993-07-01), None
patent: WO 97/31930 (1997-09-01), None
patent: WO 98/03531 (1998-01-01), None
patent: WO 00/09530 (2000-02-01), None
patent: WO 01/60833 (2001-08-01), None
patent: WO 02/018403 (2002-07-01), None
The Merck Manual, 17thedition, p. 283.
Peeters, T.L., Current Opinion in Investigational Drugs, 2(4), (2001), 555-557 (abstract.
Clark et al., Clinical and Experimental Pharmacology and Physiology (1999) 26, 242-245.
Dtsch. Z. Verdau Stoffwechselkr, (1986); 46(2):122-9 (abstract).
Miller et al., Peptides, 21 (2000) 283-287.
O. Alaradi et al; “Irritable bowel syndrome: update on pathogenesis and management”;Med Principles Pract; vol. 11, p. 2-17, 2002.
M. Bradette, et al; “Effect of motilin and erythromycin on the motor activity of the human colon”;J. Gastrointest. Mot. , vol. 5, pp. 247-251, 1993.
D. M. Chieppa, et al; Effects of erythromycin on human colonic circular muscle in idiopathic chronic constipation,European Journal of Clinical Investigation; vol. 30, pp. 66-71, 2000.
D. Harari et al; “Correlates of regular laxative use by frail elderly persons”;The American Journal of Medicine, vol. 99, pp. 513-518.
Zen Itoh; “Motilin and Clinical Application”;Peptides, vol. 18, No. 4, pp. 593-608, 1997.
J. S. Jameson et al; “Oral or intravenous erythromycin has no effect on human distal colonic motility”;Aliment, Pharmacol. Ther., vol. 6, pp. 589-595, 1992.
I.M.C. Kamerling et al; “Dose-related effects of motilin on proximal gastrointestinal motility”;Ailment Pharmacol Ther; vol. 16, pp. 129-135, 2002.
I.M.C. Kamerling et al; “Exogenous motilin affects postprandial proximal gastric motor function and visceral sensation”;Digestive Diseases and Sciences; vol. 47, No. 8, pp. 1732-1736, 2002.
H. Koga et al; “Design, SAR and pharmacology of GM-611, the first acid-stable non-peptide motilin receptor agonist”;Drugs of the Future; vol. 27, No. 3; pp. 255-272, 2002.
Y.C. Luiking et al; “Motilin induces gall bladder emptying and antral contractions in the fasted state in humans”;Gut; vol. 42, pp. 830-835, 1998.
M. Pappagallo: “Incidence, Prevalence, and Management of Opioid Bowel Dysfunction”;The American Journal of Surgery; vol. 182, pp. 11S-18S; 2001.
S. Sharma et al “Effect of oral erythromycin on colonic transit in patients with idiopathic constipation”;Digestive Diseases and Sciences, vol. 40, No. 11, pp. 2446-2449, 1995.
D. Thorpe; “Management of Opioid-induced Constipation”;Curr. Pain Headache Rep., vol. 5, pp. 237-240, 2001.
Cynshi Osamu
Kamei Kenshi
Ozaki Kenichi
Sato Hideki
Sudo Hirokazu
Browdy & Neimark PLLC
Chugai Seiyaku Kabushiki Kaisha
Spivack Phyllis G.
LandOfFree
Methods of treating dyschezia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating dyschezia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating dyschezia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096215